David M. Weiner joins Lumos Pharma as Chief Medical Officer to steer development of the company's rare and orphan disease therapeutics. He comes to Lumos from aTyr Pharma, where he was Chief Medical Officer.
Last month the firm welcomed John C. McKew as its Chief Scientific Officer.
Dr Weiner has more than 20 years of experience in the discovery and clinical development of novel therapeutics for neurological disease, and has held a number of senior executive roles at private and public biotechnology companies. Prior to aTyr, he was Chief Medical Officer and interim Chief Executive of Proteostasis Therapeutics.
He also held key development roles over a five-year period at EMD/Merck Serono, and spent almost a decade in a series of discovery research and clinical development roles at Acadia Pharmaceuticals.
John McKew
Dr McKew was also at aTyr Pharma before joining Lumos, where as Vice President of Research, he was responsible for leading research aimed at harnessing the therapeutic potential of tRNA synthetases.
Prior to aTyr Pharma, he was acting Scientific Director of the Division of Preclinical Innovation at the NCATS/NIH. There, he was responsible for developing the TRND and the Bridging Interventional Development Gaps (BrIDGs) programmes. Before this, Dr McKew was a director at Wyeth Research and began his career at Genetics Institute.
